Tirzepatide is administered subcutaneously once weekly at doses ranging from 2.5 mg to 15 mg, with gradual dose escalation recommended to minimize gastrointestinal adverse effects
GLP-1 therapy injections represent a groundbreaking advancement in the treatment of obesity and significant weight loss
It mimics the GLP-1 hormone that targets areas of the brain that regulate appetite and food intake, making it a critical tool for medical weight loss supervised by specialists like OBGYNs
These medicines have become increasingly important in the management of type 2 diabetes and, more recently, obesity
Mohiuddin MS, Himeno T, Inoue R, Miura-Yura E, Yamada Y, Nakai-Shimoda H, Asano S, Kato M, Motegi M, Kondo M, Seino Y, Tsunekawa S, Kato Y, Suzuki A, Naruse K, Kato K, Nakamura J, Kamiya H (2019) Glucagon-like Peptide-1 receptor agonist protects dorsal Root Ganglion neurons against oxidative insult
Tongue still